Incyte
INCY
$129.93
+9.30%
Incyte is a biopharmaceutical company focused on discovering and developing small-molecule drugs for oncology and dermatology. Its leading drug, Jakafi, treats rare blood cancers and graft-versus-host disease, and it markets several other oncology and dermatology products. The company is distinct as a commercial-stage biotech with a strong pipeline and a partnership with Novartis. Current investor attention centers on Incyte's growth trajectory, driven by Jakafi's continued strength and the recent approval of Opzelura for vitiligo, as well as a $1.25 billion bet on a rare bleeding disorder drug that could expand its hematology franchise.…
INCY
Incyte
$129.93
Related headlines
INCY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Incyte's 12-month outlook, with a consensus price target around $115.48 and implied upside of -11.1% versus the current price.
Average Target
$115.48
0 analysts
Implied Upside
-11.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$71 - $140
Analyst target range
Incyte is covered by 22 analysts, with a consensus recommendation of 'Buy' (mean score 2.31 on a 1-5 scale, where 1 is Strong Buy). The average target price is $114.55, which implies a 2.7% downside from the current price of $117.67. The distribution shows 10 Buy ratings, 7 Hold, and 5 Sell (implied from the mean), indicating a moderately bullish consensus. The target range is wide: low $71.00 and high $140.00. The high target of $140 implies 19% upside and likely assumes successful pipeline execution and market share gains for Opzelura. The low target of $71 suggests a 40% downside, possibly pricing in Jakafi patent cliffs or pipeline failures. Recent ratings from Barclays (Overweight), BMO (Market Perform), and RBC (Sector Perform) show a mix of bullish and neutral stances. The wide spread between high and low targets signals high uncertainty, typical for biotech stocks with binary pipeline events.
Bulls vs Bears: INCY Investment Factors
Incyte presents a compelling mix of strong financials, attractive valuation, and growth potential, but faces concentration risk and limited near-term upside. The bull case is supported by 20.87% revenue growth, high margins, and a clean balance sheet, while the bear case highlights Jakafi dependence and a modest analyst target. The single most important tension is whether Incyte can diversify its revenue stream beyond Jakafi through Opzelura and pipeline drugs; success would validate the growth story and justify a higher multiple, while failure could lead to multiple compression. Currently, the bull case has stronger evidence given the valuation support and profitability, but the stock's proximity to its 52-week high limits immediate upside.
Bullish
- Strong Revenue Growth: Revenue grew 20.87% YoY in Q1 2026 to $1.273B, accelerating from prior quarters. This growth is driven by Jakafi's continued strength and Opzelura's expansion, indicating robust commercial execution.
- Attractive Valuation: Trailing PE of 14.99x and forward PE of 13.05x are near the low end of Incyte's 5-year range (7x-185x). The PEG ratio of 0.004 suggests the stock is cheap relative to its earnings growth rate.
- High Profitability Margins: Gross margin of 91.8% and net margin of 23.8% in Q1 2026 demonstrate strong pricing power and operational efficiency. Operating margin of 25.5% is stable and healthy.
- Strong Balance Sheet: Debt-to-equity of 0.013 and current ratio of 3.32 indicate minimal leverage and ample liquidity. Free cash flow TTM of $1.45B provides flexibility for R&D and acquisitions.
Bearish
- Jakafi Revenue Concentration: Jakafi contributed $863M of Q1 2026 revenue (67.8%), exposing Incyte to patent expiration or competitive pressure. Any setback for Jakafi would significantly impact overall revenue.
- Limited Upside to Analyst Target: The average analyst target of $114.55 implies a 2.7% downside from the current price of $117.67. Even the high target of $140 offers only 19% upside, capping near-term return potential.
- High Uncertainty in Pipeline: The wide range of analyst targets ($71-$140) reflects binary outcomes from pipeline events. The $1.25B bet on a rare bleeding disorder drug carries clinical and regulatory risk.
- Potential Overbought Technicals: The stock is trading at 98.4% of its 52-week high, suggesting near-term overextension. While momentum is strong, a pullback from these levels is possible.
INCY Technical Analysis
Incyte is in a sustained uptrend, with the stock price up 66.93% over the past year, significantly outperforming the S&P 500's 16.47% gain. The current price of $117.67 sits at 98.4% of its 52-week range (high $119.60, low $69.69), indicating strong momentum and near-term overextension. This positioning near the high suggests bullish sentiment but also raises the risk of a pullback. Short-term momentum is accelerating: the 1-month price change is +8.49%, and the 3-month change is +24.32%, both outpacing the S&P 500's 0.78% and 3.50% respectively. The relative strength index (RSI) is not directly provided, but the consistent upward move implies overbought conditions. The divergence between the 1-month and 1-year trends is minimal, as both are positive, reinforcing the strength of the uptrend. The stock's beta of 0.758 indicates it is less volatile than the market, which is unusual for a biotech but suggests lower systematic risk. Key support lies at the 52-week low of $69.69, while resistance is at the 52-week high of $119.60. A breakout above $119.60 would signal a continuation of the uptrend, while a breakdown below $69.69 would be a bearish reversal. Given the low beta, the stock may offer a smoother ride than peers.
Beta
0.76
0.76x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$71-$133
Price range past year
Annual Return
+85.2%
Cumulative gain past year
| Period | INCY Return | S&P 500 |
|---|---|---|
| 1m | +14.2% | +1.6% |
| 3m | +31.1% | +4.1% |
| 6m | +28.5% | +6.8% |
| 1y | +85.2% | +16.3% |
| ytd | +28.1% | +8.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INCY Fundamental Analysis
Incyte's revenue is growing robustly, with Q1 2026 revenue of $1.273 billion, up 20.87% year-over-year from $1.053 billion in Q1 2025. The multi-quarter trend shows acceleration: Q2 2025 revenue was $1.216 billion, Q3 2025 was $1.366 billion, and Q4 2025 was $1.507 billion. Jakafi remains the primary driver, contributing $863 million in Q1 2026, while Opzelura is a fast-growing segment at $143 million. The growth trajectory supports the investment case, though reliance on Jakafi is a concentration risk. Profitability is solid: net income for Q1 2026 was $303 million, with a net margin of 23.8%. Gross margin is exceptionally high at 91.8%, typical for biotech with low cost of goods sold. Operating margin of 25.5% is healthy and has been stable over recent quarters, indicating efficient cost management. The company is consistently profitable, with positive net income in each of the last four quarters. The balance sheet is strong: debt-to-equity ratio is a mere 0.013, indicating minimal leverage. Free cash flow (TTM) is $1.451 billion, providing ample liquidity for R&D and acquisitions. The current ratio of 3.32 reflects strong short-term liquidity. ROE of 24.9% is excellent, signaling efficient use of equity. Incyte is self-funding its growth and does not rely on external financing.
Quarterly Revenue
$1.3B
2026-03
Revenue YoY Growth
+20.9%
YoY Comparison
Gross Margin
91.8%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INCY Overvalued?
Since Incyte has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 14.99x, while the forward PE is 13.05x, implying the market expects earnings growth. The gap between trailing and forward PE suggests a modest growth premium. Compared to the biotechnology industry average PE (not provided, but typically higher for growth names), Incyte's PE appears reasonable given its strong margins and growth. The PS ratio of 3.75x is low for a biotech with high gross margins, indicating potential undervaluation relative to sales. Historically, Incyte's trailing PE has ranged from about 7x to 185x over the past five years. The current 14.99x is near the lower end of that range, suggesting the stock is not overvalued by historical standards. The PEG ratio of 0.004 is extremely low, implying the stock is cheap relative to its earnings growth rate, though this may be distorted by a very high growth estimate. Overall, valuation appears attractive, with the market not fully pricing in the growth trajectory.
PE
15.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Incyte's revenue is heavily concentrated in Jakafi, which accounted for 67.8% of Q1 2026 revenue. Any loss of exclusivity or competitive erosion could severely impact earnings. The company's net margin of 23.8% is healthy, but operating expenses (R&D of $516M in Q1) are high relative to revenue, leaving little room for error. The debt-to-equity ratio of 0.013 is negligible, so balance sheet risk is low, but the $1.25B acquisition bet on a rare bleeding disorder drug introduces execution risk and could pressure cash flows if the drug fails.
Market & Competitive Risks: Incyte's beta of 0.758 indicates lower market correlation than typical biotech, but the stock is still sensitive to sector sentiment and regulatory news. The average analyst target of $114.55 suggests limited upside, and the wide range ($71-$140) reflects high uncertainty. Competitive threats include new JAK inhibitors for myelofibrosis and vitiligo, which could erode Jakafi and Opzelura market share. Recent news of the $1.25B bet on a rare bleeding disorder drug highlights the risk of large pipeline investments with binary outcomes.
Worst-Case Scenario: If Jakafi faces unexpected patent challenges or pipeline drugs fail, the stock could fall to the analyst low target of $71, representing a 39.7% decline from the current price of $117.67. This scenario would likely involve multiple compression and earnings downgrades. The 52-week low of $69.69 provides a floor, but a sustained downturn could test that level. In such a scenario, an investor could lose approximately 40% of their investment.